Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00543504 · ClinicalTrials.gov registry record · Phase 1
Bevacizumab in Multiple Phase I Combinations
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 343
- Enrollment target
NCT00543504: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00543504 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 343 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00543504, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 343 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of Avastin™ that can be given in combination with 4 other study drug/drug combinations. It will be given with sunitinib, with sorafenib, with a combination of erlotinib and cetuximab, and with a combination of trastuzumab and lapatinib. The safety and effectiveness of these drug combinations will also be studied.
Interventions
- DRUG Trastuzumab
- DRUG Bevacizumab
- DRUG Sorafenib
- DRUG Erlotinib
- DRUG Lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 343 participants |
| Start Date | 2007-10-10 |
| Est. Completion | 2020-04-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00543504
The ClinicalTrials.gov registry entry for NCT00543504 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 343 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Trastuzumab is the first listed.
NCT00543504 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00543504 about?
NCT00543504 is a clinical study titled "Bevacizumab in Multiple Phase I Combinations". The goal of this clinical research study is to find the highest tolerable dose of Avastin™ that can be given in combination with 4 other study drug/drug combinations. It will be given with sunitinib, with sorafenib, with a combination of erlotinib and cetuximab, and with a combination of trastuzumab...
What is the current status of trial NCT00543504?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 343 participants. The study started on 2007-10-10. Estimated completion is 2020-04-29.
What interventions are being tested in trial NCT00543504?
The interventions under investigation include: Trastuzumab (DRUG), Bevacizumab (DRUG), Sorafenib (DRUG), Erlotinib (DRUG), Lapatinib (DRUG).
Who is sponsoring clinical trial NCT00543504?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.